The enhancement of non viral vectors is a priority in the field of gene therapy, in order to manage effective and safe vectorsi. Among non viral vectors, solid lipid nanoparticles (SLN) have emerged in the last years as an alternative to liposomes and PEI (poly-ethylene-imine) and many efforts have been spent in order to improve their performanceii. The present study aims to design and characterize in vitro multicomposite SLN as a novel platform for pDNA delivery: SLN matrix composition was modified by assembling several components able to optimize the carrier in terms of transfection efficieny and safety. In details, stearic acid was selected as the main lipid component along with stearylamine as its analogous cationic compound. Protamine and Pluronic F68 were included in the formulation as transfection promoter and surfactant, respectively. Cholesterol (Chol) and phosphatidylcholine (PC) were added to improve biocompatibility and plasticity of the carriers.
In vitro behaviour of multicomposite cationic SLN as new platform for pDNA delivery / Vighi, Eleonora; Iannuccelli, Valentina; Coppi, Gilberto; Leo, Eliana Grazia. - ELETTRONICO. - ND:(2011), pp. ND-ND. (Intervento presentato al convegno 2011 Annual Workshop CRS - Nanostructured Devices for Drug Delivery: from Small Molecules to Biotech Drugs tenutosi a Roma nel 17-19 novembre 2011).
In vitro behaviour of multicomposite cationic SLN as new platform for pDNA delivery
VIGHI, Eleonora;IANNUCCELLI, Valentina;COPPI, Gilberto;LEO, Eliana Grazia
2011
Abstract
The enhancement of non viral vectors is a priority in the field of gene therapy, in order to manage effective and safe vectorsi. Among non viral vectors, solid lipid nanoparticles (SLN) have emerged in the last years as an alternative to liposomes and PEI (poly-ethylene-imine) and many efforts have been spent in order to improve their performanceii. The present study aims to design and characterize in vitro multicomposite SLN as a novel platform for pDNA delivery: SLN matrix composition was modified by assembling several components able to optimize the carrier in terms of transfection efficieny and safety. In details, stearic acid was selected as the main lipid component along with stearylamine as its analogous cationic compound. Protamine and Pluronic F68 were included in the formulation as transfection promoter and surfactant, respectively. Cholesterol (Chol) and phosphatidylcholine (PC) were added to improve biocompatibility and plasticity of the carriers.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
